BioStock: PHI’s CEO comments on the approved US listing
![](https://phiab.com/wp-content/uploads/2024/08/Biostock-PHI-CEO-comments-on-the-approved-US-listing.jpg)
Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.
Read the full interview with Patrik Eschricht on biostock.se.
Further reading
![HoloMonitor M4 with logo](https://phiab.com/wp-content/uploads/2019/04/HoloMonitorM4-and-logo-landscape.jpg)
CEO interview in BioStock
In the article published today by BioStock, the company’s CEO Peter Egelberg comments on the developments during the past autumn.
![](https://phiab.com/wp-content/uploads/2018/07/Mold-Examination-1200x800.jpg)
Scientists at UCSF-PHI Center of Excellence map the genetic progression of invasive skin cancer
Utilizing precision genetic engineering and PHI’s HoloMonitor technology, scientists at University of California, San Francisco, have for the first time been able to monitor and map how mutations break down the genetic protection against skin cancer.